FollowMyHealth Patient Portal

Faculty Physicians

Daniel W. Coyne, MD

Professor, Medicine
Division of Renal Diseases
Director, Hemodialysis, Chromalloy American Kidney Center
Director, Outpatient Renal Clinics

Specialty Areas

Nephrology
Kidney Disease
Dialysis Management

Board Certifications

Internal Medicine
Nephrology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Chronic kidney disease, hemodialysis, high blood pressure, hypertension, proteinuria, hematuria, anemia

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Medicine Multispecialty Center

4921 Parkview Place
St. Louis, MO 63110

Suite: C
Floor: 5
Office Phone: 314-362-7603
Fax: 314-747-3743

Davita St. Louis Dialysis

2610 Clark Avenue
St. Louis, MO 63103

Office Phone: 314-534-0909
Fax: 314-534-0661

Chromalloy American Kidney Center

4950 Children's Place
St. Louis , MO 63110

Office Phone: 314-362-7209
Fax: 314-362-7232

Center for Advanced Medicine - South County

5201 Midamerica Plaza
St. Louis, MO 63129

Office Phone: 314-362-7603
Fax: 314-747-5213

Education

Education

Fellowship: Nephrology, Washington University School of Medicine, St. Louis, Missouri 1989
Residency: Internal Medicine, Emory University Medicine Program, Atlanta, Georgia 1986
Medical Degree: Case Western Reserve, Cleveland, Ohio 1983
B.A.: Chemistry, St. Louis University, St. Louis, Missouri 1979

Publication & Research

Publication & Research

Use of 2MD, a Novel Oral Calcitriol Analog, in Hemodialysis Patients with Secondary Hyperparathyroidism.
Pandey R, Zella J, Clagett-Dame M, Plum LA, DeLuca HF, Coyne DW
Am J Nephrol. 2016 Apr 21; 43(3)213-220.

PMID:
    27096733
    [PubMed - as supplied by publisher]
Related citations


Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
Macdougall IC, Bircher AJ, Eckardt KU, Obrador GT, Pollock CA, Stenvinkel P, Swinkels DW, Wanner C, Weiss G, Chertow GM, Conference Participants
Kidney Int. 2016 Jan; 89(1)28-39. doi: 10.1016/j.kint.2015.10.002.

PMID:
    26759045
    [PubMed - in process]
Related citations


Data confusion.
Bhandari S, Kalra PA, Coyne DW
Kidney Int. 2015 Dec; 88(6)1445. doi: 10.1038/ki.2015.303.

PMID:
    26649663
    [PubMed - as supplied by publisher]
Related citations


Relationship of 1,25 dihydroxy Vitamin D Levels to Clinical Outcomes in Critically Ill Patients with Acute Kidney Injury.
Vijayan A, Li T, Dusso A, Jain S, Coyne DW
J Nephrol Ther. 2015 Feb; 5(1)pii: 190.

PMID:
    26295008
    [PubMed]
Related citations


A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
Kalra PA, Bhandari S, Saxena S, Agarwal D, Wirtz G, Kletzmayr J, Thomsen LL, Coyne DW
Nephrol Dial Transplant. 2015 Aug 6; pii: gfv293.

PMID:
    26250435
    [PubMed - as supplied by publisher]
Related citations


A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.
Bhandari S, Kalra PA, Kothari J, Ambühl PM, Christensen JH, Essaian AM, Thomsen LL, Macdougall IC, Coyne DW
Nephrol Dial Transplant. 2015 Sep; 30(9)1577-89. doi: 10.1093/ndt/gfv096.

PMID:
    25925701
    [PubMed - indexed for MEDLINE]
Related citations


Considerations and challenges in defining optimal iron utilization in hemodialysis.
Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S, Dialysis Advisory Group of the American Society of Nephrology
J Am Soc Nephrol. 2015 Jun; 26(6)1238-47. doi: 10.1681/ASN.2014090922.

PMID:
    25542967
    [PubMed - indexed for MEDLINE]
Related citations


Evaluating the safety and rationale for cinacalcet posttransplant hyperparathyroidism and hypercalcemia.
Coyne DW, Delos Santos R
Am J Transplant. 2014 Nov; 14(11)2446-7. doi: 10.1111/ajt.12913.

PMID:
    25223316
    [PubMed - indexed for MEDLINE]
Related citations


A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.
Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM
Clin J Am Soc Nephrol. 2014 Sep 5; 9(9)1620-6. doi: 10.2215/CJN.10661013.

PMID:
    24970869
    [PubMed - indexed for MEDLINE]
Related citations


Anemia in chronic kidney disease treating the numbers, not the patients.
Coyne DW
JAMA Intern Med. 2014 May; 174(5)708-9.

PMID:
    24589715
    [PubMed - indexed for MEDLINE]
Related citations


The KDOQI US commentary on KDIGO anemia guideline and quality of life.
Coyne DW
Am J Kidney Dis. 2014 Mar; 63(3)540. doi: 10.1053/j.ajkd.2013.08.037.

PMID:
    24560158
    [PubMed - indexed for MEDLINE]
Related citations


Update on intravenous iron choices.
Larson DS, Coyne DW
Curr Opin Nephrol Hypertens. 2014 Mar; 23(2)186-91. doi: 10.1097/01.mnh.0000441154.40072.2e.

PMID:
    24401789
    [PubMed - indexed for MEDLINE]
Related citations


Should we sweat the small (micro) things?
Scott MG, Coyne DW
Clin Chem. 2014 Mar; 60(3)435-7. doi: 10.1373/clinchem.2013.218800.

PMID:
    24363371
    [PubMed - indexed for MEDLINE]
Related citations


Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study.
Coyne DW, Andress DL, Amdahl MJ, Ritz E, de Zeeuw D
Nephrol Dial Transplant. 2013 Sep; 28(9)2260-8. doi: 10.1093/ndt/gft227.

PMID:
    23787544
    [PubMed - indexed for MEDLINE]
Related citations


Anemia management in dialysis: Why the FDA and CMS have it right (and how KDIGO got it wrong).
Coyne DW
Nephrol News Issues. 2013 Feb; 27(2)16, 18, 20.

PMID:
    23469454
    [PubMed - indexed for MEDLINE]
Related citations


Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease.
Larson DS, Coyne DW
Kidney Res Clin Pract. 2013 Mar; 32(1)11-5. doi: 10.1016/j.krcp.2013.01.001.

PMID:
    26894030
    [PubMed]
Related citations


Bioavailable vitamin D in chronic kidney disease.
Brown AJ, Coyne DW
Kidney Int. 2012 Jul; 82(1)5-7. doi: 10.1038/ki.2012.135.

PMID:
    22699377
    [PubMed - indexed for MEDLINE]
Related citations


Very Low Density Lipoprotein Metabolism in Patients with Chronic Kidney Disease.
Wang X, Belani S, Coyne DW, Fabbrini E, Reeds DN, Patterson BW, Mittendorfer B, Klein S
Cardiorenal Med. 2012 Feb; 2(1)57-65.

PMID:
    22493604
    [PubMed]
Related citations


The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial.
Coyne DW
Kidney Int. 2012 Jul; 82(2)235-41. doi: 10.1038/ki.2012.76.

PMID:
    22437411
    [PubMed - indexed for MEDLINE]
Related citations


Hepcidin: clinical utility as a diagnostic tool and therapeutic target.
Coyne DW
Kidney Int. 2011 Aug; 80(3)240-4. doi: 10.1038/ki.2011.141.

PMID:
    21677632
    [PubMed - indexed for MEDLINE]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following earned financial interests during calendar year 2014.

Company Name: Abbvie

Royalties:

Equity: No

Consulting/Advisory Board:

Speaker Fees: $10,001 - $25,000

Reporting Date: May 01, 2016


Company Name: Aspire

Royalties:

Equity: No

Consulting/Advisory Board: $10,001 - $25,000

Speaker Fees:

Reporting Date: May 01, 2016


Company Name: Fresenius

Royalties:

Equity: No

Consulting/Advisory Board: $10,001 - $25,000

Speaker Fees: $10,001 - $25,000

Reporting Date: May 01, 2016


Company Name: Hospira

Royalties:

Equity: No

Consulting/Advisory Board: $1,000 - $10,000

Speaker Fees: $10,001 - $25,000

Reporting Date: May 01, 2016